FDA
-
-
-
-
-
-
-
3rd Quarter Results
-
-
-
-
-
-
-
Caladrius Biosciences Reports 2018 First Quarter Financial Results
-
-
-
-
-
-
-
Caladrius Biosciences (CLBS) Acquires License to Late Stage CD34+ Cell Therapy Program for Treatment of Refractory Angina
-
-
-
-
-
-
-
Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
-
-
-
-
-
-
-
Shire plc (SHPG): Cutting PT After Generic Arrives Earlier Than Expected - Jefferies
-
-
-
-
-
-
-
Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura
-
-
-
-
-
-
-
Shire Responds to U.S. Federal Trade Commission Civil Action
-
322,256 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

